



Mexico City, March 22nd, 2017

Nexus Capital announces investment in IMMUNOTEC

Nexus Capital announces that on March 22, 2017 it has signed the agreements to realize an investment in Immuno Holding, S.A. de C.V., a company that, through its subsidiaries after closing of the transaction (“IMMUNOTEC”), is focused on the development and commercialization of nutritional supplements through multi-level direct sales channels.

The investment will be realized in association with Mauricio Domenzain, who has ample industry experience in Mexico, the United States and other countries, as a former executive of a prominent direct selling company. The management team that has driven IMMUNOTEC’s success will continue under the direction of Mauricio Domenzain.

The investment will be carried out by Nexus VI (Nexus Capital Private Equity Fund VI, L.P. and Nexxus Capital VI Trust (NEXX6CK 13)), subject to certain approvals and closing conditions.

IMMUNOTEC is a company with over 20 years of leadership. Its products are commercialized through multi-level direct sales channels mainly in Mexico, with presence in other countries, including the United States and Canada. Among the broad product portfolio that IMMUNOTEC offers is the Immunocal family of products, which has brought health benefits to consumers for over 20 years.

According to the World Federation of Direct Selling Associations, the nutritional supplements category has become the category with the largest size and growth in the global direct sales industry.

About Nexus Capital

Nexus Capital has actively contributed to the private equity industry in Mexico since its foundation in 1995. It is one of the leading alternative asset managers in Mexico and one of the most successful in Latin America.

Considering this investment, Nexus Capital has completed 25 investments and has fully divested from 11 portfolio companies. Nexus Capital has raised and managed five funds through seven investment vehicles with capital commitments of over US\$1.2 billion, and is the only Mexican alternative asset manager that has listed five portfolio companies in the public markets.

The investment in IMMUNOTEC is the seventh investment of Nexus VI, as it continues to analyze equity investment opportunities in Mexican mid-sized companies with high growth potential, whose value can be enhanced through strategic acquisitions, improved operations, and the implementation of world-class business standards.

Nexus Capital strives to be the Mexican alternative asset manager with whom investors, entrepreneurs and service providers prefer to associate with due to its value creation capabilities, acting with complete transparency, integrity and professionalism.

For further information on Nexus Capital please visit www.nexxuscapital.com or contact:

Investor Relations
ir@nexxuscapital.com
+52 (55) 5292-3400